Purpose of this Study
We are doing this study to find out if an experimental drug called pacritinib (the study drug) is a safe and effective treatment for people with T-cell lymphoproliferative cancers. We want to know how well it works for patients diagnosed with peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL).
Who Can Participate?
Eligibility
Adults ages 18+ diagnosed with PTCL or CTCL that has relapsed or failed to respond to treatment.
For more information about who can join this study, please contact the study team at <a href= "mailto: terri.lucas@duke.edu">terri.lucas@duke.edu.</a>
For more information about who can join this study, please contact the study team at <a href= "mailto: terri.lucas@duke.edu">terri.lucas@duke.edu.</a>
What is Involved?
If you choose to join this study, you will go through a screening period to find out if you are eligible. During this screening period, you will:<ul>
<li>Have a physical exam</li>
<li>Have a heart scan (ECG, Echo)</li>
<li>Have blood draws</li>
<li>Have bone marrow samples taken (PTCL patients only)</li>
<li>Have a tissue biopsy (lymph node)</li>
<li>Have a skin biopsy (CTCL patients only)</li>
<li>Have imaging (PET/CT)</li></ul>
If you are eligible to continue in the study after screening, you will begin taking the study drug. The study drug is a capsule that you take by mouth, and you will take the study drug every day at the same time. You will take the study drug for as long as the study doctor believes you are receiving a benefit.
<li>Have a physical exam</li>
<li>Have a heart scan (ECG, Echo)</li>
<li>Have blood draws</li>
<li>Have bone marrow samples taken (PTCL patients only)</li>
<li>Have a tissue biopsy (lymph node)</li>
<li>Have a skin biopsy (CTCL patients only)</li>
<li>Have imaging (PET/CT)</li></ul>
If you are eligible to continue in the study after screening, you will begin taking the study drug. The study drug is a capsule that you take by mouth, and you will take the study drug every day at the same time. You will take the study drug for as long as the study doctor believes you are receiving a benefit.
Study Details
Full Title
Phase 2, open label, multicenter study of pacritinib in relapsed/refractory T-cell
lymphoproliferative neoplasms
lymphoproliferative neoplasms
Principal Investigator
Jie
Wang
Protocol Number
PRO00113497
NCT ID
NCT04858256
Phase
II
Enrollment Status
Pending Open to Enrollment